Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
SAFETY, ACTIVITY, AND PHARMACOKINETICS OF GLQ223 IN PATIENTS WITH AIDS AND AIDS-RELATED COMPLEX
Autore:
KAHN JO; GORELICK KJ; GATTI G; ARRI CJ; LIFSON JD; GAMBERTOGLIO JG; BOSTROM A; WILLIAMS R;
Indirizzi:
SAN FRANCISCO GEN HOSP,AIDS PROGRAM,WARD 84,995 POTRERO AVE SAN FRANCISCO CA 94110 UNIV CALIF SAN FRANCISCO,DEPT MED SAN FRANCISCO CA 94110 GENELABS TECHNOL INC REDWOOD CITY CA 94063 CRUNCH SOFTWARE OAKLAND CA 94621 US FDA WASHINGTON DC 20204 UNIV CALIF SAN FRANCISCO,DEPT CLIN PHARM SAN FRANCISCO CA 94110
Titolo Testata:
Antimicrobial agents and chemotherapy
fascicolo: 2, volume: 38, anno: 1994,
pagine: 260 - 267
SICI:
0066-4804(1994)38:2<260:SAAPOG>2.0.ZU;2-A
Fonte:
ISI
Lingua:
ENG
Soggetto:
HUMAN-IMMUNODEFICIENCY-VIRUS; POKEWEED ANTIVIRAL PROTEIN; HUMAN MONOCYTE-MACROPHAGES; HIV REPLICATION; CELLS; INHIBITION; AZIDOTHYMIDINE; TRICHOSANTHIN; ANTIBODIES; INFECTION;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Science Citation Index Expanded
Citazioni:
27
Recensione:
Indirizzi per estratti:
Citazione:
J.O. Kahn et al., "SAFETY, ACTIVITY, AND PHARMACOKINETICS OF GLQ223 IN PATIENTS WITH AIDS AND AIDS-RELATED COMPLEX", Antimicrobial agents and chemotherapy, 38(2), 1994, pp. 260-267

Abstract

GLQ223 is a highly purified single-chain ribosome-inactivating protein with selective effects against a variety of cells, including macrophages infected with human immunodeficiency virus. We evaluated the safety, pharmacokinetics, and immunologic effects of multiple doses of GLQ223 in 22 patients with AIDS or AIDS-related complex; CD4(+) T-cell counts were between 100 and 350/mm(3). GLQ223 was administered intravenously at doses of 8, 16, 24, 36, and 50 mu g/kg of body weight; the drug was administered by constant infusion over 3 h to achieve a concentration in serum of 50 ng/ml; this concentration is known to be associated with anti-HIV effects in vitro. All patients reported a flu-like syndrome characterized by muscle and joint aches and an increase in creatinine kinase levels; symptoms were controlled easily. For patients who received 36 and 50 mu g/kg, target concentrations in serum were achieved and an increase in CD4(+) and CD8(+) T cells was sustained; this sustained increase persisted for at least 28 days after the last infusion. beta(2)-Microglobulin levels increased during the infusions and then declined when the infusions ended. Repeat infusions of GLQ223 weresafe and relatively well tolerated. The target concentration of GLQ223 in serum was achieved and sustained. Our results suggest that GLQ223may have activity in treating patients with human immunodeficiency virus infection.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 04/04/20 alle ore 14:16:40